Gentronix expands sales teams in US and Europe

Appoints Dorothy Zelent and Simon Johns

Gentronix, a UK-based provider of genotoxicity assays and contract testing services, has expanded its sales teams with the appointments of Dorothy Zelent as director of North American Operations, and Simon Johns as European sales director. They will report to commercial director Steve Beasley.

With an extensive background in molecular biotechnology, Zelent has more than 10 years’ experience in academic and pharmaceutical research. A graduate of the University of Pennsylvania, she previously conducted research into diabetes drug discovery before joining GlaxoSmithKline as a senior scientist in cardiovascular drug discovery. She also brings broad project management skills to Gentronix from previous positions as director of business development for a number of clinical research technology companies.

Simon Johns

Simon Johns

Johns has a technical background in microbiology and genetics, as well as more than 20 years’ international commercial experience supporting clients in the pharmaceutical, biotechnology and chemical sectors. With his early research activities including the development of genotoxicity imaging systems, Johns has since worked extensively within the pre-clinical toxicology sector for several major global CROs in both Europe and the US.

You may also like

Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Subscribe now